Bjerre

About Steen Bjerre

This author has not yet filled in any details.
So far Steen Bjerre has created 213 blog entries.

Oral formulation rapidly absorbed

2018-11-16T22:54:27+00:00

BioCryst Pharmaceuticals, Inc. presents data showing that an oral formulation of BCX7353 was rapidly absorbed and exhibited a long half-life, two important characteristics of desired new acute treatments for HAE attacks. In the trial, the pharmacokinetic (PK) and kallikrein inhibition profiles of BCX7353 were evaluated for 24 hours post-dose in six subjects with HAE Type I or II [...]

Significant, clinically meaningful reduction of HAE attacks

2018-11-16T08:26:27+00:00

Shire plc has announced additional data from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study, evaluating the efficacy and safety of subcutaneously administered Lanadelumab in HAE. Data shows that patients treated with Lanadelumab 300 mg every two weeks experienced significantly fewer HAE attacks, were less likely to have moderate or severe attacks or use rescue medication [...]

More aggressive development plan for HAE candidate

2018-11-13T16:47:49+00:00

“Thanks to our recent equity financing and the exciting Phase 1 data from our HAE candidate KVD900, we are pleased to announce that we are building on these successes with a more aggressive development plan for KVD900, to potentially accelerate our time to market,” says Andrew Crockett, CEO of KalVista Pharmaceuticals, Inc. “Our first step [...]

CHMP Recommends EU Marketing Authorisation of Lanadelumab

2018-10-25T13:29:14+00:00

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorisation of Lanadelumab injection for routine prevention of recurrent attacks of HAE in patients aged 12 years and older. If approved, Lanadelumab will be a first-of-its-kind, fully human monoclonal antibody (mAb) available [...]

“Global Perspectives” #3/2018 out now

2018-09-26T18:05:08+00:00

Dear HAE friends, We have just released the third 2018 issue of the HAEi magazine ’Global Perspectives’. Once more we give you a comprehensive insight into a great number of HAE related things going on around the globe. Among the topics in the magazine you will find an article on the additions to our Regional [...]

Firazyr approved for HAE attacks in Japan

2018-09-21T08:47:05+00:00

The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted manufacturing and marketing authorization for Firazyr for the acute treatment of HAE attacks in adult patients. “As a long-term partner to the HAE community, we continually strive to bring treatments to those living with HAE around the world,” said Andreas Busch, Ph.D., Executive [...]

Health Canada authorizes TAKHZYRO

2018-09-20T13:40:57+00:00

Shire plc and Shire Pharma Canada ULC (Shire Canada) announces that following priority review, Health Canada has authorized TAKHZYRO (lanadelumab injection) for routine prevention of attacks of HAE in adolescents and adults (12 years of age and older). "The burden HAE patients and their families face every day can’t be ignored,” said Jacquie Badiou, President, HAE Canada. “Our [...]

Additional clinical trial data for prophylaxis of HAE requested

2018-09-26T17:37:26+00:00

Pharming Group N.V. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the supplemental Biologics License Application (sBLA) for Ruconest [C1 Esterase Inhibitor (recombinant)] to expand the current indication to include prophylaxis in patients with HAE. In November 2017, following feedback from FDA on two completed trials of [...]

KalVista Reports First Quarter Results

2018-09-14T17:11:20+00:00

From the KalVista Pharmaceuticals, Inc. financial results for the fiscal first quarter ended July 31, 2018: “Our recent financings provide significant additional capital for late-stage development of KVD900, our oral plasma kallikrein inhibitor for potential treatment of on-demand acute attacks in patients with HAE,” said Andrew Crockett, CEO. Additionally, we remain committed to our work [...]

BioCryst reports positive results in trial

2018-09-06T16:48:55+00:00

BioCryst Pharmaceuticals, Inc. announces the initial results from the ZENITH-1 trial showing that a single 750 mg oral dose of BCX7353 was well tolerated and superior to placebo (p<0.05) against the majority of efficacy endpoints evaluated in HAE patients suffering an acute attack. BCX7353 is a novel oral plasma kallikrein inhibitor being developed for both [...]